Navigation Links
Baxter International Third Quarter 2008 Financial Results Conference Call
Date:9/17/2008

DEERFIELD, Ill., Sept. 17 /PRNewswire-FirstCall/ -- Baxter International (NYSE: BAX), will host a quarterly conference call to discuss its third quarter 2008 financial results on Thursday, October 16, 2008, at 8:30 a.m. Eastern Time (7:30 a.m. Central Time). To access the call, please dial 866- 238-0637 (domestic) or 703-639-1156 (international). Please dial into the call at least ten minutes prior to the start of the call for the operator to connect you.

This call is being webcast by Thomson/CCBN and can be accessed at Baxter's Web site at http://www.baxter.com/. The conference call will be recorded by Baxter and is copyrighted material. It cannot be recorded or rebroadcast without Baxter's permission.

The webcast is also being distributed through the Thomson StreetEvents Network. Individual investors can listen to the call at http://www.earnings.com, Thomson's individual investor portal, powered by StreetEvents. Institutional investors can access the call via Thomson StreetEvents (http://www.streetevents.com), a password-protected event management site.

Baxter International Inc. develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, cancer, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide.

Contact Information:

Investor Relations Conta
'/>"/>

SOURCE Baxter International Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Baxter Named to Dow Jones Sustainability Index for Tenth Consecutive Year
2. Baxter Announces Licensing Agreement for Innocolls Gentamicin Surgical Implant in the United States
3. Baxter Declares Quarterly Dividend
4. Baxter Raises Full-Year 2008 Outlook Following Strong Second-Quarter Financial Results
5. Bioniche Pharma Acquires Baxters ENLON(R) and ENLON-PLUS(R)
6. Baxters Board of Directors Declares Quarterly Dividend
7. Baxter Reports Solid First Quarter Financial Results and Raises Full-Year Outlook
8. Baxters V-Link Luer-Activated Device With VitalShield Protective Coating Now Available For Hospitals
9. Baxter Announces FDA Approval of ARTISS Slow-Setting Fibrin Sealant in Treatment of Burn Patients
10. Baxters Board of Directors Approves New Share Repurchase Authorization of $2 Billion
11. Baxter and Its Foundation Contribute Nearly $53 Million in 2007 to Address Critical Needs Locally and Globally
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... NY (PRWEB) June 18, 2013 In ... and sustainability, the Consulate General of Switzerland in New ... boat, Switzerland’s MS Tûranor PlanetSolar , to Manhattan. ... of its DeepWater Expedition 2013 tour with scientists on ... by Capitain Gérard d’Aboville, runs exclusively on energy from ...
(Date:6/18/2013)... Demanding industrial and environmental conditions are no ... and Glass Ball Lenses, now available in an extensive ... , of Philadelphia , PA. , Optical Ball Lenses ... beams without the need for direct physical contact. That’s ... mohs) make it the ideal choice for fiber-optic applications ...
(Date:6/18/2013)... AZ (PRWEB) June 18, 2013 Nasseo, ... 2013 Innovation Challenge Winner out of hundreds of applicants ... its spring Arizona Innovation Challenge . The Arizona ... country for a technology commercialization challenge, granting a financial ... most promising technology ventures. Nasseo’s state of the art ...
(Date:6/18/2013)... ATLANTA , June 18, 2013  regulated information ... Jeff Klauk today announced the launch of ... their loved ones. The Pledge ... take a stand and make a personal commitment to ... with their health care team and additional partial-onset seizure ...
Breaking Biology Technology:Switzerland’s MS Tûranor PlanetSolar, the World’s Largest Solar Boat, Arrives in New York City 2Switzerland’s MS Tûranor PlanetSolar, the World’s Largest Solar Boat, Arrives in New York City 3Switzerland’s MS Tûranor PlanetSolar, the World’s Largest Solar Boat, Arrives in New York City 4Swiss Jewel Introduces the Crown Jewels of Fiber-Optic Connectors 2Nasseo Named 2013 Innovation Challenge Winner by Arizona Commerce Authority 2Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy 2Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy 3Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy 4Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy 5Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy 6
... 31 China Agro-Technology,Holdings Ltd ("CAT") today announced that ... Executive Officer, replacing interim CEO Harry,He, effective as of ... York., CAT is a leading agro-biotechnology company listed ... company reported total audited revenues of,US$37 million in fiscal ...
... DIEGO, Jan. 31 /PRNewswire-FirstCall/ - MIGENIX Inc.,(TSX: MGI, ... infectious,diseases, will add a 600mg celgosivir combination therapy ... study in hepatitis C virus,("HCV") treatment-naive patients. The ... and Institutional Review Board (IRB) approvals. The,purpose of ...
... Research Initiatives in Search of a Cure and Therapies ... ... 31 The Christopher and Dana,Reeve Foundation (CDRF), which is dedicated ... quality of life for people,living with paralysis through grants, information and ...
Cached Biology Technology:China Agro-Technology Appoints New CEO 2China Agro-Technology Appoints New CEO 3MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study 2MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study 3MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study 4MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study 5MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study 6Christopher and Dana Reeve Foundation Awards Nearly $2 Million in Individual Research Grants 2Christopher and Dana Reeve Foundation Awards Nearly $2 Million in Individual Research Grants 3
(Date:6/19/2013)... In fall 2012, the European Medicines Agency (EMA) ... the first ever gene therapy for clinical use ... company, had developed AAV-LPL S447X for the treatment ... lipase deficiency (LPLD) which affects approximately one or ... causes severe, life-threatening inflammations of the pancreas. Afflicted ...
(Date:6/18/2013)...  Paris Air Show – Marvin Test ... a leading provider of innovative test solutions for ... solutions this week at the Paris Air ... including increasingly complex armament systems with longer lifecycles, ... test solutions that address legacy system obsolescence. Marvin ...
(Date:6/18/2013)... Energy Department,s National Renewable Energy Laboratory (NREL), and ... paper describing a novel cellulose-degrading enzyme from a ... known as the gribble. , Gribbles are ... ability to produce their own enzymes instead of ... they eat. New biomass-degrading enzymes from novel sources ...
Breaking Biology News(10 mins):No danger of cancer through gene therapy virus 2Marvin Test Solutions Demonstrates Next-Generation Armament Test Solutions at Paris Air Show 2Marvin Test Solutions Demonstrates Next-Generation Armament Test Solutions at Paris Air Show 3Novel enzyme from tiny gribble could prove a boon for biofuels research 2
... have discovered a new source of stems cells and ... vessel, nerve and liver cells in the laboratory. The ... cells from the amniotic fluid that surrounds developing embryos ... is that these cells will provide a valuable resource ...
... Immune cells that are the body’s front-line defense don’t ... on their outside skins and rouse them to action, ... Michigan scientists describe their findings that bacteria can barge ... immune response. , The study, published online ahead ...
... ocean circulation and sea levels in the centuries to come? ... zones in the oceans on the rise? Can aquaculture be ... the collapse of coastal fisheries? , Most importantly, what can ... of the news media are invited to join leading international ...
Cached Biology News:Scientists discover new, readily available source of stem cells 2Scientists discover new, readily available source of stem cells 3Microbes start immune response by sneaking inside cells 2Are we killing the world's oceans? 2